Clinical trial · no report yet · Phase 2
NEST3
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
- NCT07595874 ↗
- Recruiting
- City of Hope Medical Center
- 10 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIB Rectal Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage IIC Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8
- Interventions
- Balstilimab; Biospecimen Collection; Botensilimab; Computed Tomography; Magnetic Resonance Imaging
- Arms
- Treatment (botensilimab and balstilimab) · Experimental
- Enrollment
- 100 (estimated)
- Primary outcomes
- Two-year disease-free survival rate
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI)
- Start
- Dec 27, 2026 (estimated)
- Primary completion
- May 27, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07595874 · updated Jul 1, 2026